Therapeutic efficacy and safety of plasmapheresis in elderly patients with neuromyelitis optica spectrum disorder: a single-center observational study

被引:3
|
作者
Zhang, Weihe [1 ]
Jiao, Yujuan [2 ]
Cui, Lei [2 ]
Zhang, Yeqiong [2 ]
Jiao, Jinsong [2 ]
Jin, Ming [3 ]
Yuan, Wei [3 ]
You, Yang [4 ]
Wang, Renbin [2 ]
Peng, Dantao [1 ]
机构
[1] China Japan Friendship Hosp, Dept Neurol, 2 Yinghua, Beijing 100029, Peoples R China
[2] China Japan Friendship Hosp, Dept Neurol, Beijing, Peoples R China
[3] China Japan Friendship Hosp, Dept Ophthalmol, Beijing, Peoples R China
[4] 964 Hosp Peoples Liberat Army, Dept Neurol, Changchun, Peoples R China
关键词
efficacy; elderly; neuromyelitis optica spectrum disorder; plasma exchange; safety; PLASMA-EXCHANGE; DIAGNOSTIC-CRITERIA; OUTCOMES; MARKER; ATTACK; AGE;
D O I
10.1177/17562864231162420
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background:Neuromyelitis optica spectrum disorder (NMOSD) is a devastating autoimmune disorder with cycles of escalating relapse. Rates of diagnosis in the elderly are increasing. Therapeutic decision-making is more challenging in elderly patients due to multiple comorbidities and high risk of drug-induced side effects. Objective:This retrospective study assessed the efficacy and safety of standard plasma exchange (PLEX) treatment in an elderly population with NMOSD. Design:Seventy-six patients with NMOSD who received PLEX were apportioned to two groups as either elderly (> 60 years, n = 26) or young (<60 years) at the time of the first procedure. Methods:Therapeutic response was judged according to functional recovery at 6 months, as reflected by Expanded Disability Status Scale (EDSS) and visual outcome scale (VOS) scores. Results:The mean age of the 26 elderly patients was 67.7 +/- 7.9 years (range 60-87 years); the population was predominantly female (88.5%). PLEX sessions were generally well tolerated among the elderly. Compared with the young patients, the elderly had significantly more comorbidities and concomitant medications. Twenty-four (96.0%) elderly patients showed functional improvement at 6 months after PLEX, of which 15 (60.0%) experienced moderate-to-marked improvement. Six months after the initial PLEX treatment, the patients overall experienced a significant improvement in EDSS and VOS scores. Logistic regression showed that severe optic neuritis attack was a significant independent prognostic factor associated with poor PLEX response. The groups were comparable regarding overall or serious adverse events. The rate of transient hypotension was significantly higher in the elderly compared with the young. Conclusion:PLEX is an effective and safe therapy for elderly patients with NMOSD and should be considered a treatment option during NMOSD attacks. In the elderly, preventive measures against hypotension are recommended before PLEX.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] The efficacy of therapeutic apheresis in patients with refractory neuromyelitis optica spectrum disorders: a single-center retrospective study
    Zhang, Leiying
    Zhuang, Yuan
    Liu, Xiaomin
    Xu, Quangang
    Zhou, Lingling
    Zou, Liyang
    Jiang, Ying
    Tian, Jing
    Yao, Huan
    Chi, Hongxu
    Qiu, Xuede
    Yang, Tianxin
    Wang, Deqing
    Yu, Yang
    ANNALS OF PALLIATIVE MEDICINE, 2021, 10 (03) : 3105 - 3114
  • [2] Insights into neuromyelitis optica spectrum disorder and pregnancy from a single-center study in Thailand
    Budtarad, Nuttakarn
    Ongphichetmehta, Tatchaporn
    Siritho, Sasitorn
    SCIENTIFIC REPORTS, 2025, 15 (01):
  • [3] Safety and efficacy of rituximab in neuromyelitis optica spectrum disorder
    Radaelli, M.
    Moiola, L.
    Privitera, D.
    Rodegher, M.
    Colombo, B.
    Barcella, V.
    Sangalli, F.
    Esposito, F.
    Comi, G.
    Martinelli, V.
    JOURNAL OF NEUROLOGY, 2011, 258 : 261 - 262
  • [4] Relapses and Serious Infections in Patients with Neuromyelitis Optica Spectrum Disorder Treated with Rituximab: A Swedish Single-Center Study
    Carlsson, Olof
    Jonsson, Dagur Ingi
    Brundin, Lou
    Iacobaeus, Ellen
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (02)
  • [5] Safety and efficacy of rtuximab in patients affected by neuromyelitis optica spectrum disorder
    Radaelli, M.
    Moiola, L.
    Rodegher, M.
    Colombo, B.
    Privitera, D.
    Sangalli, F.
    Barcella, V.
    Martinelli, V.
    Comi, G.
    MULTIPLE SCLEROSIS JOURNAL, 2011, 17 : S290 - S291
  • [6] Efficacy and Safety of Elobixibat in Elderly Patients with Chronic Constipation: A Single-center, Observational Study
    Abe, Tatsuya
    Kunimoto, Masao
    Hachiro, Yoshikazu
    Ohara, Kei
    Inagaki, Mitsuhiro
    Murakami, Masanori
    JOURNAL OF THE ANUS RECTUM AND COLON, 2020, 4 (03): : 122 - 127
  • [7] The efficacy and safety of mycophenolate mofetil in Thai neuromyelitis optica spectrum disorder patients
    Pathomrattanapiban, Charinya
    Tisavipat, Nanthaya
    Jitprapaikulsan, Jiraporn
    Prayoonwiwat, Naraporn
    Rattanathamsakul, Natthapon
    Siritho, Sasitorn
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 63
  • [8] Safety and Efficacy of Bortezomib in Patients With Highly Relapsing Neuromyelitis Optica Spectrum Disorder
    Zhang, Chao
    Tian, De-Cai
    Yang, Chun-Sheng
    Han, Bin
    Wang, Jing
    Yang, Li
    Shi, Fu-Dong
    JAMA NEUROLOGY, 2017, 74 (08) : 1010 - 1012
  • [9] Efficacy and safety of tacrolimus treatment for neuromyelitis optica spectrum disorder
    Bo Chen
    Qian Wu
    Gaotan Ke
    Bitao Bu
    Scientific Reports, 7
  • [10] Efficacy and safety of tacrolimus treatment for neuromyelitis optica spectrum disorder
    Chen, Bo
    Wu, Qian
    Ke, Gaotan
    Bu, Bitao
    SCIENTIFIC REPORTS, 2017, 7